Products - Renal cancer | Topic | NICE

Showing 8 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Suspected Cancer: recognition and referral
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [TSID12177]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC